Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-031606
Filing Date
2024-08-13
Accepted
2024-08-13 16:05:41
Documents
42
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 449398
2 ex10-1.htm EX-10.1 58342
3 ex31-1.htm EX-31.1 17577
4 ex31-2.htm EX-31.2 17581
5 ex32-1.htm EX-32.1 8074
  Complete submission text file 0001493152-24-031606.txt   2166848

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE telo-20240630.xsd EX-101.SCH 16902
7 XBRL CALCULATION FILE telo-20240630_cal.xml EX-101.CAL 27214
8 XBRL DEFINITION FILE telo-20240630_def.xml EX-101.DEF 55686
9 XBRL LABEL FILE telo-20240630_lab.xml EX-101.LAB 145508
10 XBRL PRESENTATION FILE telo-20240630_pre.xml EX-101.PRE 115862
44 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 163913
Mailing Address 900 WEST PLATT STREET, SUITE 200 TAMPA FL 33606
Business Address 900 WEST PLATT STREET, SUITE 200 TAMPA FL 33606 (813) 864-2562
Telomir Pharmaceuticals, Inc. (Filer) CIK: 0001971532 (see all company filings)

EIN.: 872606031 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41952 | Film No.: 241201361
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)